Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice
AbstractRandomized controlled trials (RCTs) are typically conducted in highly selected patient populations to ideally demonstrate unconfounded clinical efficacy of a drug. In the real world, there may be confounding factors, such as comorbidities or less frequent monitoring. It has therefore become...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Biotechnology & Biotechnological Equipment |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13102818.2023.2268753 |
| _version_ | 1797367486467801088 |
|---|---|
| author | Manoela Manova Jeliazko Arabadjiev Radoslav Mangaldzhiev Assen Dudov Daniel Penchev Margit Hemetsberger Arkadi Sharkov Boryana Zidarova Dimitrina Apostolova Maria Vasileva Silvia Terezova Mila Vlaskovska Alexandra Savova |
| author_facet | Manoela Manova Jeliazko Arabadjiev Radoslav Mangaldzhiev Assen Dudov Daniel Penchev Margit Hemetsberger Arkadi Sharkov Boryana Zidarova Dimitrina Apostolova Maria Vasileva Silvia Terezova Mila Vlaskovska Alexandra Savova |
| author_sort | Manoela Manova |
| collection | DOAJ |
| description | AbstractRandomized controlled trials (RCTs) are typically conducted in highly selected patient populations to ideally demonstrate unconfounded clinical efficacy of a drug. In the real world, there may be confounding factors, such as comorbidities or less frequent monitoring. It has therefore become standard practice in many countries to validate findings from RCTs against available real-world datasets. The present analysis investigated a real-world evidence (RWE) cohort of Bulgarian patients treated with ribociclib in combination with letrozole or fulvestrant and compared the clinical benefit rate (CBR, defined as complete remission [CR] or partial remission [PR] or stable disease [SD]) and progression-free survival (PFS) and overall survival (OS) with pivotal RCTs. Data from 812 patients treated between 2018 and 2022 were used. The number of patients at risk was statistically robust to compare PFS and OS during the earlier periods of the real-world data analysis with the corresponding RCTs. Baseline characteristics (age, hormone receptor status, status of newly diagnosed vs. existing, previous treatments, performance status and tumor stage) were largely comparable between the RWE cohort and the RCTs. The RWE cohorts corroborated RCT findings of a CBR benefit of the ribociclib plus letrozole or fulvestrant combination compared to letrozole or fulvestrant alone. In the periods of adequate statistical robustness, PFS and OS were comparable within 95% confidence intervals (CIs) with RCT findings. This analysis found that patients with comparable characteristics use ribociclib in the real-world similarly to what has been investigated in the RCTs. Real-world effectiveness and outcomes of ribociclib combination therapy were comparable with observations from RCTs. |
| first_indexed | 2024-03-08T17:19:00Z |
| format | Article |
| id | doaj.art-92ac34f305ed40eebf4528bee4735acc |
| institution | Directory Open Access Journal |
| issn | 1310-2818 1314-3530 |
| language | English |
| last_indexed | 2024-03-08T17:19:00Z |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Biotechnology & Biotechnological Equipment |
| spelling | doaj.art-92ac34f305ed40eebf4528bee4735acc2024-01-03T09:44:12ZengTaylor & Francis GroupBiotechnology & Biotechnological Equipment1310-28181314-35302023-12-0137110.1080/13102818.2023.2268753Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practiceManoela Manova0Jeliazko Arabadjiev1Radoslav Mangaldzhiev2Assen Dudov3Daniel Penchev4Margit Hemetsberger5Arkadi Sharkov6Boryana Zidarova7Dimitrina Apostolova8Maria Vasileva9Silvia Terezova10Mila Vlaskovska11Alexandra Savova12Department of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaMedical oncology, University Hospital Acibadem City Clinic Tokuda, Sofia, BulgariaSpecialized Hospital for Active Treatment of Oncological Diseases Ltd, Sofia, BulgariaAcibadem City Clinic Mladost Hospital, Sofia, BulgariaSqilline, Sofia, BulgariaHemetsberger Medical Services, Vienna, AustriaDepartment of Communication, Faculty of Journalism, Sofia University ‘St. Kliment Ohridski’, Sofia, BulgariaNational Council on Prices and Reimbursement of Medicinal Products, Sofia, BulgariaNational Council on Prices and Reimbursement of Medicinal Products, Sofia, BulgariaNational Council on Prices and Reimbursement of Medicinal Products, Sofia, BulgariaNational Council on Prices and Reimbursement of Medicinal Products, Sofia, BulgariaNational Council on Prices and Reimbursement of Medicinal Products, Sofia, BulgariaDepartment of Organization and Economics of Pharmacy, Faculty of Pharmacy, Medical University of Sofia, Sofia, BulgariaAbstractRandomized controlled trials (RCTs) are typically conducted in highly selected patient populations to ideally demonstrate unconfounded clinical efficacy of a drug. In the real world, there may be confounding factors, such as comorbidities or less frequent monitoring. It has therefore become standard practice in many countries to validate findings from RCTs against available real-world datasets. The present analysis investigated a real-world evidence (RWE) cohort of Bulgarian patients treated with ribociclib in combination with letrozole or fulvestrant and compared the clinical benefit rate (CBR, defined as complete remission [CR] or partial remission [PR] or stable disease [SD]) and progression-free survival (PFS) and overall survival (OS) with pivotal RCTs. Data from 812 patients treated between 2018 and 2022 were used. The number of patients at risk was statistically robust to compare PFS and OS during the earlier periods of the real-world data analysis with the corresponding RCTs. Baseline characteristics (age, hormone receptor status, status of newly diagnosed vs. existing, previous treatments, performance status and tumor stage) were largely comparable between the RWE cohort and the RCTs. The RWE cohorts corroborated RCT findings of a CBR benefit of the ribociclib plus letrozole or fulvestrant combination compared to letrozole or fulvestrant alone. In the periods of adequate statistical robustness, PFS and OS were comparable within 95% confidence intervals (CIs) with RCT findings. This analysis found that patients with comparable characteristics use ribociclib in the real-world similarly to what has been investigated in the RCTs. Real-world effectiveness and outcomes of ribociclib combination therapy were comparable with observations from RCTs.https://www.tandfonline.com/doi/10.1080/13102818.2023.2268753Ribociclibbreast cancerBulgariareal-world dataoutcomes |
| spellingShingle | Manoela Manova Jeliazko Arabadjiev Radoslav Mangaldzhiev Assen Dudov Daniel Penchev Margit Hemetsberger Arkadi Sharkov Boryana Zidarova Dimitrina Apostolova Maria Vasileva Silvia Terezova Mila Vlaskovska Alexandra Savova Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice Biotechnology & Biotechnological Equipment Ribociclib breast cancer Bulgaria real-world data outcomes |
| title | Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice |
| title_full | Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice |
| title_fullStr | Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice |
| title_full_unstemmed | Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice |
| title_short | Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice |
| title_sort | adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor positive human epidermal growth factor receptor 2 negative breast cancer treated in routine bulgarian clinical practice |
| topic | Ribociclib breast cancer Bulgaria real-world data outcomes |
| url | https://www.tandfonline.com/doi/10.1080/13102818.2023.2268753 |
| work_keys_str_mv | AT manoelamanova adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT jeliazkoarabadjiev adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT radoslavmangaldzhiev adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT assendudov adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT danielpenchev adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT margithemetsberger adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT arkadisharkov adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT boryanazidarova adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT dimitrinaapostolova adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT mariavasileva adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT silviaterezova adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT milavlaskovska adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice AT alexandrasavova adequateeffectivenessofribociclibplusletrozoleorfulvestrantinpatientswithadvancedormetastatichormonereceptorpositivehumanepidermalgrowthfactorreceptor2negativebreastcancertreatedinroutinebulgarianclinicalpractice |